Sjogren's syndrome Clinical Trials

A listing of Sjogren's syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 221 clinical trials
Featured trial
Disease Modification in Sjogren's Syndrome Measured by Ultrasound

Disease Modification in Sjogren's Syndrome Measured by Ultrasound

  • 1113 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Double-Masked , Randomized, Multi-Center Phase1/2 Study to Evaluate the Efficacy and Safety of the Drug in Subjects with Dry Eye Associated with Sjogren's Syndrome.

A Double-Masked , Randomized, Multi-Center Phase1/2 Study to Evaluate the Efficacy and Safety of the Drug in Subjects with Dry Eye Associated with Sjogren's Syndrome.

  • 978 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 248 views
  • 25 Mar, 2021
  • 1 location
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS) (phaethuSA)

Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by

  • 123 views
  • 09 Sep, 2022
  • 39 locations
COVID-19 VACCINE SAFETY AND EFFECTIVENESS

A longitudinal open-label study will include health professionals and patients with immune-mediated inflammatory diseases (IMID) who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-thrid dose), in the vaccination campaign against SARS-CoV-2 to assess the …

Accepts healthy volunteers
  • 0 views
  • 02 Dec, 2021
  • 1 location
Systems Strengthening Interventions to Improve Quality and Co-coverage of Nutrition Services in Gujarat, India

Progress on child growth outcomes such as stunting requires both direct and indirect actions across multiple sectors. Recognizing the importance of multisector approaches in reducing child undernutrition, Alive & Thrive (A&T) India aims to improve the quality of health and nutrition services, as well as their convergence at the household …

Accepts healthy volunteers
  • 0 views
  • 27 Jul, 2022
  • 1 location
New Clinical End-points in Patients With Primary Sjögren's Syndrome (NECESSITY)

There are no approved treatments for pSS and the clinical endpoints currently used in clinical trials are inadequate to capture all aspects of the disease that should be evaluated in clinical trials. The newly developed composite endpoint: Sjögren's Tool for Assessing Response to treatment (STAR) will allow a more specific …

  • 4 views
  • 14 May, 2022
  • 1 location
A Post-Market Clinical Follow-up Investigation to Verify Performance and Safety of Viiral®Nasal Spray in Subjects With Dry Nose Symptoms

the study, a nasal spray with isotonic saline solution will be used. In this study, a total of 78 women and men who have been diagnosed with dry nose / rhinitis sicca will be included in the study

  • 15 views
  • 11 Mar, 2022
  • 1 location
Topical Infliximab for Sterile Corneal Melt

a sterile corneal melt (without an infection) caused by diseases such as rosacea, Sjogren's syndrome, rheumatoid arthritis, Crohn's disease, Stevens Johnson syndrome, as well as toxic epidermal

  • 11 views
  • 24 Feb, 2022
  • 1 location
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Malignancies (Keynote-D20)

iRECIST can be applied for efficacy assessment) and subjects with cutaneous T-cell lymphoma (CTCL), specifically Sézary Syndrome (SS) and mycosis fungoides (MF). The study will consist of 2 phases

  • 38 views
  • 19 Sep, 2022
  • 5 locations